A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Feb 19, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for a type of hair loss called Central Centrifugal Cicatricial Alopecia (CCCA), which mainly affects middle-aged women of African descent. The treatment involves using a special cap that emits LED light, known as the Revian Red All LED cap. The goal is to see if this cap can help reduce symptoms like scalp discomfort, prevent further hair loss, and encourage hair growth in areas that are not yet scarred. This is important because CCCA can lead to permanent hair loss and affect a person's quality of life.

To participate in the study, women aged 18 and older with a confirmed diagnosis of CCCA (Stage II-III) are eligible, provided they have been on stable treatment for at least three months without any changes. The study is currently recruiting participants from outpatient dermatology clinics. If you join, you can expect to wear the LED cap for about 10 minutes each day, and there are minimal side effects reported. This study aims to find a better way to manage CCCA and improve the lives of those affected.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women who are eighteen years of age or older with a biopsy-proven diagnosis of CCCA Stage II-III. They also must be on stable treatment without changes (on doxycycline, topical steroids, minoxidil and/or post 8 rounds of intralesional steroids) for at least 3 months.
• • Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.
• • Exclusion Criteria
• • Subjects with other forms of hair loss that is not CCCA
• • Prior treatment with light source for alopecia
• • Males are excluded from this study since the prevalence of CCCA in males is so significantly low that it is difficult to find cases in a clinical setting